Published in Neuroreport on March 01, 2004
Sequestration of free cholesterol in cell membranes by prions correlates with cytoplasmic phospholipase A2 activation. BMC Biol (2008) 1.06
Interferon-gamma increases neuronal death in response to amyloid-beta1-42. J Neuroinflammation (2006) 0.90
Ginkgolide B inhibits the neurotoxicity of prions or amyloid-beta1-42. J Neuroinflammation (2004) 0.83
Alzheimer's disease and age-related memory decline (preclinical). Pharmacol Biochem Behav (2011) 0.83
Glimepiride reduces the expression of PrPc, prevents PrPSc formation and protects against prion mediated neurotoxicity in cell lines. PLoS One (2009) 0.82
Ginkgolides protect against amyloid-beta1-42-mediated synapse damage in vitro. Mol Neurodegener (2008) 0.81
Protection of PMS777, a new AChE inhibitor with PAF antagonism, against amyloid-beta-induced neuronal apoptosis and neuroinflammation. Cell Mol Neurobiol (2009) 0.79
AChE Inhibition-based Multi-target-directed Ligands, a Novel Pharmacological Approach for the Symptomatic and Disease-modifying Therapy of Alzheimer's Disease. Curr Neuropharmacol (2016) 0.77
PMS777, a bis-interacting ligand for PAF receptor antagonism and AChE inhibition, attenuates PAF-induced neurocytotoxicity in SH-SY5Y cells. Cell Mol Neurobiol (2007) 0.77
Cholesterol synthesis inhibitors protect against platelet-activating factor-induced neuronal damage. J Neuroinflammation (2007) 0.76
Inhibition of cytosolic Phospholipase A2 prevents prion peptide-induced neuronal damage and co-localisation with Beta III Tubulin. BMC Neurosci (2012) 0.76
Squalestatin alters the intracellular trafficking of a neurotoxic prion peptide. BMC Neurosci (2007) 0.76
Current Understanding of Platelet-Activating Factor Signaling in Central Nervous System Diseases. Mol Neurobiol (2016) 0.75
Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. Proc Natl Acad Sci U S A (2010) 2.86
Identification by redox proteomics of glutathionylated proteins in oxidatively stressed human T lymphocytes. Proc Natl Acad Sci U S A (2002) 2.35
A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. Science (2009) 2.30
Glutathionylation of human thioredoxin: a possible crosstalk between the glutathione and thioredoxin systems. Proc Natl Acad Sci U S A (2002) 2.00
Mutant prion protein expression is associated with an alteration of the Rab GDP dissociation inhibitor alpha (GDI)/Rab11 pathway. Mol Cell Proteomics (2009) 1.52
Prion protein accumulation and neuroprotection in hypoxic brain damage. Am J Pathol (2004) 1.52
Tetracyclines affect prion infectivity. Proc Natl Acad Sci U S A (2002) 1.39
Amyloid-β-induced synapse damage is mediated via cross-linkage of cellular prion proteins. J Biol Chem (2011) 1.29
Insoluble mutant SOD1 is partly oligoubiquitinated in amyotrophic lateral sclerosis mice. J Biol Chem (2006) 1.26
Protein nitration in a mouse model of familial amyotrophic lateral sclerosis: possible multifunctional role in the pathogenesis. J Biol Chem (2005) 1.26
Gene expression profiling of the preclinical scrapie-infected hippocampus. Biochem Biophys Res Commun (2005) 1.21
Squalestatin cures prion-infected neurons and protects against prion neurotoxicity. J Biol Chem (2004) 1.19
Neuropathology of the recessive A673V APP mutation: Alzheimer disease with distinctive features. Acta Neuropathol (2010) 1.16
The SIRT1 activator resveratrol protects SK-N-BE cells from oxidative stress and against toxicity caused by alpha-synuclein or amyloid-beta (1-42) peptide. J Neurochem (2009) 1.15
Characterization of detergent-insoluble proteins in ALS indicates a causal link between nitrative stress and aggregation in pathogenesis. PLoS One (2009) 1.10
Phospholipase A2 inhibitors or platelet-activating factor antagonists prevent prion replication. J Biol Chem (2004) 1.08
Sequestration of free cholesterol in cell membranes by prions correlates with cytoplasmic phospholipase A2 activation. BMC Biol (2008) 1.06
Lipid-based nanoparticles with high binding affinity for amyloid-beta1-42 peptide. Biomaterials (2010) 1.06
Simvastatin treatment prolongs the survival of scrapie-infected mice. Neuroreport (2007) 1.04
JNK regulates APP cleavage and degradation in a model of Alzheimer's disease. Neurobiol Dis (2009) 1.00
Longitudinal amyloid imaging in mouse brain with 11C-PIB: comparison of APP23, Tg2576, and APPswe-PS1dE9 mouse models of Alzheimer disease. J Nucl Med (2013) 1.00
Proteomic analysis of spinal cord of presymptomatic amyotrophic lateral sclerosis G93A SOD1 mouse. Biochem Biophys Res Commun (2006) 0.99
Specific recognition of biologically active amyloid-β oligomers by a new surface plasmon resonance-based immunoassay and an in vivo assay in Caenorhabditis elegans. J Biol Chem (2012) 0.97
Inducible cytokine gene expression in the brain in the ME7/CV mouse model of scrapie is highly restricted, is at a strikingly low level relative to the degree of gliosis and occurs only late in disease. J Gen Virol (2003) 0.97
Functionalization with ApoE-derived peptides enhances the interaction with brain capillary endothelial cells of nanoliposomes binding amyloid-beta peptide. J Biotechnol (2011) 0.96
The efficacy of tetracyclines in peripheral and intracerebral prion infection. PLoS One (2008) 0.96
Tetracycline and its analogues protect Caenorhabditis elegans from β amyloid-induced toxicity by targeting oligomers. Neurobiol Dis (2010) 0.96
Effect of tetracyclines on the dynamics of formation and destructuration of beta2-microglobulin amyloid fibrils. J Biol Chem (2010) 0.96
Expression of mutant or cytosolic PrP in transgenic mice and cells is not associated with endoplasmic reticulum stress or proteasome dysfunction. PLoS One (2011) 0.96
Conformational plasticity of the Gerstmann-Sträussler-Scheinker disease peptide as indicated by its multiple aggregation pathways. J Mol Biol (2008) 0.95
Neurodegeneration induced by clustering of sialylated glycosylphosphatidylinositols of prion proteins. J Biol Chem (2012) 0.95
The neurotoxicity of prion protein (PrP) peptide 106-126 is independent of the expression level of PrP and is not mediated by abnormal PrP species. Mol Cell Neurosci (2005) 0.94
α-synuclein induced synapse damage is enhanced by amyloid-β1-42. Mol Neurodegener (2010) 0.93
Microglia kill amyloid-beta1-42 damaged neurons by a CD14-dependent process. Neuroreport (2004) 0.93
Curcumin-decorated nanoliposomes with very high affinity for amyloid-β1-42 peptide. Biomaterials (2010) 0.92
Functionalization of liposomes with ApoE-derived peptides at different density affects cellular uptake and drug transport across a blood-brain barrier model. Nanomedicine (2011) 0.92
Phospholipase A2 inhibitors protect against prion and Abeta mediated synapse degeneration. Mol Neurodegener (2010) 0.92
In vivo fate of avidin-nucleic acid nanoassemblies as multifunctional diagnostic tools. ACS Nano (2013) 0.92
Interferon-gamma increases neuronal death in response to amyloid-beta1-42. J Neuroinflammation (2006) 0.90
Soluble Aβ oligomer-induced synaptopathy: c-Jun N-terminal kinase's role. J Mol Cell Biol (2013) 0.90
Genomics of elite sporting performance: what little we know and necessary advances. Adv Genet (2013) 0.90
Manipulation of PrPres production in scrapie-infected neuroblastoma cells. J Neurosci Methods (2004) 0.89
The glycosylphosphatidylinositol anchor is a major determinant of prion binding and replication. Biochem J (2010) 0.89
Monoacylated cellular prion protein modifies cell membranes, inhibits cell signaling, and reduces prion formation. J Biol Chem (2011) 0.89
Squalestatin protects neurons and reduces the activation of cytoplasmic phospholipase A2 by Abeta(1-42). Neuropharmacology (2007) 0.89
Oleuropein aglycone protects transgenic C. elegans strains expressing Aβ42 by reducing plaque load and motor deficit. PLoS One (2013) 0.88
Overcoming synthetic Abeta peptide aging: a new approach to an age-old problem. Amyloid (2009) 0.88
The molecular assembly of amyloid aβ controls its neurotoxicity and binding to cellular proteins. PLoS One (2011) 0.88
Use of surface plasmon resonance to study the elongation kinetics and the binding properties of the highly amyloidogenic Aβ(1-42) peptide, synthesized by depsi-peptide technique. Biosens Bioelectron (2010) 0.88
The aldehyde oxidase gene cluster in mice and rats. Aldehyde oxidase homologue 3, a novel member of the molybdo-flavoenzyme family with selective expression in the olfactory mucosa. J Biol Chem (2004) 0.87
Glycosylphosphatidylinositol anchor analogues sequester cholesterol and reduce prion formation. J Biol Chem (2010) 0.87
A modified protocol to prepare seed-free starting solutions of amyloid-β (Aβ)₁₋₄₀ and Aβ₁₋₄₂ from the corresponding depsipeptides. Anal Biochem (2010) 0.87
A new face for old antibiotics: tetracyclines in treatment of amyloidoses. J Med Chem (2013) 0.86
Novel approaches for studying amyloidogenic peptides/proteins. Curr Opin Pharmacol (2013) 0.86
The N-methylated peptide SEN304 powerfully inhibits Aβ(1-42) toxicity by perturbing oligomer formation. Biochemistry (2012) 0.86
Tetracyclines and prion infectivity. Infect Disord Drug Targets (2009) 0.86
Neurones treated with cyclo-oxygenase-1 inhibitors are resistant to amyloid-beta1-42. Neuroreport (2003) 0.86
Cytoplasmic domain of human myelin protein zero likely folded as beta-structure in compact myelin. Biophys J (2006) 0.86
Blood-brain barrier alterations in the cerebral cortex in experimental autoimmune encephalomyelitis. J Neuropathol Exp Neurol (2012) 0.86
Tetracycline and its analogues as inhibitors of amyloid fibrils: searching for a geometrical pharmacophore by theoretical investigation of their conformational behavior in aqueous solution. J Mol Model (2004) 0.86
Conformational polymorphism of the PrP106-126 peptide in different environments: a molecular dynamics study. J Phys Chem B (2006) 0.85
Longitudinal tracking of human fetal cells labeled with super paramagnetic iron oxide nanoparticles in the brain of mice with motor neuron disease. PLoS One (2012) 0.85
Temporal and spatial relationship between the death of PrP-damaged neurones and microglial activation. Neuroreport (2002) 0.85
Microglial cells kill prion-damaged neurons in vitro by a CD14-dependent process. J Neuroimmunol (2005) 0.85
Gerstmann-Sträussler-Scheinker disease amyloid protein polymerizes according to the "dock-and-lock" model. J Biol Chem (2005) 0.85
Prostaglandin D2 mediates neuronal damage by amyloid-beta or prions which activates microglial cells. Neuropharmacology (2005) 0.85
Good gene, bad gene: new APP variant may be both. Prog Neurobiol (2012) 0.84
Interactions of the prion peptide (PrP 106-126) with brain capillary endothelial cells: coordinated cell killing and remodeling of intercellular junctions. J Neurochem (2011) 0.84
Analysis of the cerebellar proteome in a transgenic mouse model of inherited prion disease reveals preclinical alteration of calcineurin activity. Proteomics (2006) 0.84
Different mutations at V363 MAPT codon are associated with atypical clinical phenotypes and show unusual structural and functional features. Neurobiol Aging (2013) 0.83
Ginkgolide B inhibits the neurotoxicity of prions or amyloid-beta1-42. J Neuroinflammation (2004) 0.83
Neurotoxic and gliotrophic activity of a synthetic peptide homologous to Gerstmann-Sträussler-Scheinker disease amyloid protein. J Neurosci (2007) 0.83
Galpha13 mediates activation of the cytosolic phospholipase A2alpha through fine regulation of ERK phosphorylation. Cell Signal (2006) 0.83
Channels formed with a mutant prion protein PrP(82-146) homologous to a 7-kDa fragment in diseased brain of GSS patients. Am J Physiol Cell Physiol (2003) 0.83
Redox regulation of cyclophilin A by glutathionylation. Proteomics (2006) 0.83
Docosahexaenoic and eicosapentaenoic acids increase neuronal death in response to HuPrP82-146 and Abeta 1-42. Neuropharmacology (2008) 0.83
A new fluorogenic peptide determines proteasome activity in single cells. J Med Chem (2010) 0.83
Glimepiride reduces the expression of PrPc, prevents PrPSc formation and protects against prion mediated neurotoxicity in cell lines. PLoS One (2009) 0.82
Applications of surface plasmon resonance (SPR) for the characterization of nanoparticles developed for biomedical purposes. Sensors (Basel) (2012) 0.82
Huprine-tacrine heterodimers as anti-amyloidogenic compounds of potential interest against Alzheimer's and prion diseases. J Med Chem (2012) 0.82
Tetracycline prevents Aβ oligomer toxicity through an atypical supramolecular interaction. Org Biomol Chem (2010) 0.82
Platelet-activating factor antagonists protect amyloid-beta damaged neurons from microglia-mediated death. Neuropharmacology (2006) 0.82
The anti-fibrillogenic activity of tetracyclines on PrP 106-126: a 3D-QSAR study. J Mol Model (2008) 0.82
The binding affinity of anti-Aβ1-42 MAb-decorated nanoliposomes to Aβ1-42 peptides in vitro and to amyloid deposits in post-mortem tissue. Biomaterials (2011) 0.81
Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: synthesis, biological characterization, and behavioral studies. J Med Chem (2014) 0.81
Ginkgolides protect against amyloid-beta1-42-mediated synapse damage in vitro. Mol Neurodegener (2008) 0.81
β-amyloid 1-42 induces physiological transcriptional regulation of BACE1. J Neurochem (2012) 0.81
Polyunsaturated fatty acids protect against prion-mediated synapse damage in vitro. Neurotox Res (2009) 0.81
Ethanol protects cultured neurons against amyloid-β and α-synuclein-induced synapse damage. Neuropharmacology (2011) 0.81
In vitro aggregation behavior of a non-amyloidogenic λ light chain dimer deriving from U266 multiple myeloma cells. PLoS One (2012) 0.80
Cyclo-oxygenase inhibitors protect against prion-induced neurotoxicity in vitro. Neuroreport (2002) 0.80
Benefit of doxycycline treatment on articular disability caused by dialysis related amyloidosis. Amyloid (2013) 0.80
Role of glycosylphosphatidylinositols in the activation of phospholipase A2 and the neurotoxicity of prions. J Gen Virol (2004) 0.80